A study analysing efficacy and toxicity of nivolumab combined with or without docetaxel in patients with advanced NSCLC
Latest Information Update: 21 Feb 2022
At a glance
- Drugs Docetaxel (Primary) ; Nivolumab (Primary)
- Indications Non-small cell lung cancer
- Focus Therapeutic Use
Most Recent Events
- 21 Feb 2022 New trial record
- 01 Feb 2022 Primary endpoint has been met progression-free survival (PFS), as per results published in the Cancer Immunology Immunotherapy
- 01 Feb 2022 Results published in the Cancer Immunology Immunotherapy